Literature DB >> 11191579

Short-term spontaneous improvement rates in depressed outpatients.

M A Posternak1, M Zimmerman.   

Abstract

The objectives of the present report were: a) to determine the spontaneous remission rate in depressed outpatients who do not receive antidepressant medication; b) to develop a novel method for obtaining a control group that can be used to gauge the effectiveness of antidepressant medication in clinical practice; and c) to compare response rates from the present sample with outcomes of depressed patients in our practice who were treated with antidepressant medications. By using a naturalistic design, prospective assessments were made on all depressed outpatients. Twenty-five patients who met full criteria for a major depressive episode ended up not taking antidepressant medication for a variety of reasons. "Response" rates to a no-treatment trial were determined with standard outcome criteria using the Clinical Global Impression-Improvement scale. Eight patients (32.0%) had a positive response, 5 patients (20.0%) had a partial response, and 12 patients (48.0%) were nonresponders to a no-treatment trial. These response rates were higher than expected, but significantly lower than what we had found in a cohort of depressed patients who underwent an antidepressant trial (p = .02). Likewise, treatment-resistant patients fared better on pharmacotherapy, though this difference was not statistically significant. These results suggest that the occurrence of spontaneous remissions may be common in clinical practice, and therefore the specific short-term benefits of antidepressant medication in clinical practice may frequently be overestimated. Despite the high rate of spontaneous remission in our sample, the present study allowed us to confirm the effectiveness of antidepressant medication in clinical practice using a novel method for obtaining a control comparison group.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11191579     DOI: 10.1097/00005053-200012000-00002

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  3 in total

1.  Improving study design for antidepressant effectiveness assessment.

Authors:  Florian Naudet; Bruno Millet; Jean Michel Reymann; Bruno Falissard
Journal:  Int J Methods Psychiatr Res       Date:  2013-08-30       Impact factor: 4.035

2.  A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.

Authors:  David Mischoulon; Lawrence H Price; Linda L Carpenter; Audrey R Tyrka; George I Papakostas; Lee Baer; Christina M Dording; Alisabet J Clain; Kelley Durham; Rosemary Walker; Elizabeth Ludington; Maurizio Fava
Journal:  J Clin Psychiatry       Date:  2014-04       Impact factor: 4.384

Review 3.  S-adenosyl methionine (SAMe) for depression in adults.

Authors:  Ilaria Galizia; Lucio Oldani; Karine Macritchie; Erica Amari; Dominic Dougall; Tessa N Jones; Raymond W Lam; Guido Jacopo Massei; Lakshmi N Yatham; Allan H Young
Journal:  Cochrane Database Syst Rev       Date:  2016-10-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.